Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

More than 2.5 billion adults worldwide are currently overweight or obese, according to estimates from the World Health Organization. This staggering ...

Hims & Hers ( HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk ( NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.

TD Cowen downgraded Hims & Hers Health to "Hold" from "Buy" citing a lack of near-term catalysts and concerns over the company’s weight loss revenue guidance in a post-compounded GLP-1 ...

SHOPPING: Take steps to achieve your body goals with Hers, the weight loss program that takes into account your specific ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week ...